- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02608918
Taste Properties of HIV Inhibitor
April 13, 2018 updated by: ViiV Healthcare
An Open-Label Taste Assessment of BMS-955176 in Healthy Subjects
The purpose of the study is to assess the taste properties of HIV inhibitor
Study Overview
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Woburn, Massachusetts, United States, 01801
- GSK Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
25 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
- Men and women of non-childbearing potential professional sensory panelists
- Aged between 25 and 80 years
Exclusion Criteria:
- History of relevant drug or food allergies, cardiovascular or Central nervous system (CNS) disease, clinically significant pathology, history of mental illness
- Positive HIV test
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BMS-955176
BMS-955176 specified dose on specified days
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Taste properties of HIV Inhibitor will be measured using the Flavor Profile of the Flavor Leadership Criteria
Time Frame: Up to 2 years
|
Up to 2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 5, 2016
Primary Completion (Actual)
May 24, 2016
Study Completion (Actual)
May 24, 2016
Study Registration Dates
First Submitted
November 17, 2015
First Submitted That Met QC Criteria
November 17, 2015
First Posted (Estimate)
November 20, 2015
Study Record Updates
Last Update Posted (Actual)
April 17, 2018
Last Update Submitted That Met QC Criteria
April 13, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- RNA Virus Infections
- Virus Diseases
- Infections
- Blood-Borne Infections
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Immune System Diseases
- HIV Infections
- Anti-Infective Agents
- Antiviral Agents
- Anti-HIV Agents
- Anti-Retroviral Agents
- BMS-955176
Other Study ID Numbers
- 206301
- AI468-065 (Other Identifier: Bristol-Myers Squibb)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on BMS-955176
-
ViiV HealthcareGlaxoSmithKlineTerminatedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKlineCompleted
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited Kingdom
-
ViiV HealthcareGlaxoSmithKlineCompleted
-
ViiV HealthcareGlaxoSmithKlineTerminatedInfection, Human Immunodeficiency VirusUnited States, France, Germany, Canada, Spain, United Kingdom, Mexico, Italy, Argentina, Chile, South Africa, Poland
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV Infections | Infection, Human Immunodeficiency VirusGermany
-
ViiV HealthcareCompletedHIV InfectionsUnited States
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
China National Center for Cardiovascular DiseasesPeking University People's Hospital; Beijing Chao Yang Hospital; Hebei Medical...UnknownCoronary Artery EctasiaChina
-
CelgeneRecruitingProstatic NeoplasmsUnited States